Research Topics
| Paul SugarbakerSummaryCountry: USA Publications
| Collaborators
|
Detail Information
Publications
Total abdominal colectomy, pelvic peritonectomy, and end-ileostomy for the surgical palliation of mucinous peritoneal carcinomatosis from non-gynecologic cancerKonstantinos M Stamou
Washington Cancer Institute, Washington Hospital Center, NW, Washington, DC 20010, USA
J Surg Oncol 83:197-203. 2003..It is not clear if the procedure should be advocated for more invasive gastrointestinal malignancies...
Parietal peritonectomyPaul H Sugarbaker
Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA
Ann Surg Oncol 19:1250. 2012..Generally, the parietal peritonectomy takes approximately 2½ h and does not require blood replacement. After the parietal peritonectomy, additional cytoreductive surgical procedures and then perioperative chemotherapy are performed...
Management of appendiceal pseudomyxoma peritonei diagnosed during pregnancyErika Haase
Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington Hospital Center, Washington, District of Columbia, USA
World J Surg Oncol 7:48. 2009..Epithelial tumors of the appendix on the other hand are rare and account for only approximately 1% of all colorectal neoplasms; the occurrence of this neoplasm during pregnancy is extremely rare...
Interstitial pneumonitis following intrapleural chemotherapyLuis Zappa
Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington, DC, USA
World J Surg Oncol 7:17. 2009..Treatment of this condition is by parietal and visceral pleurectomy followed by hyperthermic intrapleural chemotherapy...
Bologna Guidelines for Diagnosis and Management of Adhesive Small Bowel Obstruction (ASBO): 2010 Evidence-Based Guidelines of the World Society of Emergency SurgeryFausto Catena
Emergency Surgery Unit, Department of General and Multivisceral Transplant Surgery, S, Orsola Malpighi University Hospital, Bologna, Italy
World J Emerg Surg 6:5. 2011..abstract:..
Guidelenines in the management of obstructing cancer of the left colon: consensus conference of the world society of emergency surgery (WSES) and peritoneum and surgery (PnS) societyLuca Ansaloni
1st Unit of General Surgery, Ospedali Riuniti di Bergamo, Italy
World J Emerg Surg 5:29. 2010..abstract:..
Comprehensive management of diffuse malignant peritoneal mesotheliomaP H Sugarbaker
Program in Peritoneal Surface Oncology, Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, Suite 3900, Washington, DC 20010, USA
Eur J Surg Oncol 32:686-91. 2006..The length of the survival was dependent upon the aggressive versus indolent biology of the neoplasm, nevertheless cure was not considered as a reasonable expectation and the overall median survival was approximately one year...
Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancyPaul H Sugarbaker
Washington Cancer Institute, 106 Irving Street, N W, Suite 3900, Washington, DC 20010, USA
Ann Surg Oncol 13:635-44. 2006..Patients with these diagnoses were treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy...
Managing the peritoneal surface component of gastrointestinal cancer. Part 1. Patterns of dissemination and treatment optionsPaul H Sugarbaker
Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington, DC, USA
Oncology (Williston Park) 18:51-9. 2004..The results of combined treatment as they vary in mucinous and nonmucinous tumors are also discussed...
Hybrid ileostomyPaul H Sugarbaker
Washington Cancer Institute, Washington, District of Columbia 20010, USA
J Surg Oncol 93:161-3. 2006
The natural history, gross pathology, and histopathology of appendiceal epithelial neoplasmsP H Sugarbaker
Washington Cancer Institute, 106 Irving Street, NW, Suite 3900, Washington, DC 20010, USA
Eur J Surg Oncol 32:644-7. 2006..To report the pathology of appendiceal epithelial neoplasms a review of the Washington Cancer Institute experience and a PubMed literature search was performed...
A curative approach to peritoneal carcinomatosis from colorectal cancerPaul H Sugarbaker
Washington Cancer Institute, Washington, DC 20010, USA
Semin Oncol 32:S68-73. 2005..Because these combined treatment modalities have been investigated in large numbers of patients, the selection factors for acceptable long-term survival combined with a well-defined morbidity and mortality have become established...
Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosisP H Sugarbaker
Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, Suite 3900, Washington, DC 20010, USA
Eur J Surg Oncol 37:719-26. 2011..Doxorubicin is a drug consistently used by our group in this clinical setting. The surgical and clinical factors that modify the pharmacokinetics of HIPEC may be important for the design of future perioperative chemotherapy regimens...
Strategies for management of the peritoneal surface component of cancer: cytoreductive surgery plus perioperative intraperitoneal chemotherapyPaul H Sugarbaker
Washington Cancer Institute, Washington, DC 20010, USA
J Oncol Pharm Pract 11:111-9. 2005..A prominent part of treatment failure of gastrointestinal and gynecologic malignancy is dissemination to peritoneal surfaces. This has been associated with a limited survival and no reliable treatment strategies...
New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?Paul H Sugarbaker
Washington Cancer Institute, 106 Irving Street, NW Suite 3900 Washington, DC 20020, USA
Lancet Oncol 7:69-76. 2006..In the absence of a phase III study, this new combined treatment should be regarded as the standard of care for epithelial appendiceal neoplasms and pseudomyxoma peritonei syndrome...
An instrument to provide containment of intraoperative intraperitoneal chemotherapy with optimized distributionPaul H Sugarbaker
Washington Cancer Institute, Washington, DC 20010, USA
J Surg Oncol 92:142-6. 2005
Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin CPaul H Sugarbaker
Program in Peritoneal Surface Malignancy, Washington Cancer Institute, 106 Irving st NW, POB 3900, Washington DC, 20010, USA
Cancer Chemother Pharmacol 57:703-8. 2006..While optimizing the use of this treatment strategy, little information regarding the effect of volume of chemotherapy solution is available...
Peritoneal surface oncology: review of a personal experience with colorectal and appendiceal malignancyP H Sugarbaker
Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, Suite 3900, Washington, DC 20010, USA
Tech Coloproctol 9:95-103. 2005..Additional adjuvant phase III studies with perioperative intraperitoneal chemotherapy in diseases where peritoneal surface spread occurs are indicated...
Colorectal carcinomatosis: a new oncologic frontierPaul H Sugarbaker
Washington Cancer Institute, Washington Hospital Center, DC 20010, USA
Curr Opin Oncol 17:397-9. 2005..In the past, carcinomatosis from colorectal cancer was determined to be a lethal condition with a short survival...
The approval process for hyperthermic intraoperative intraperitoneal chemotherapyP H Sugarbaker
Washington Cancer Institute, Washington Hospital Center, 106 Irving St, NW, Suite 3900, Washington, DC 20010, USA
Eur J Surg Oncol 32:637-43. 2006..To clarify the requirements for Food and Drug Administration approval in the United States for hyperthermic intraoperative intraperitoneal chemotherapy administration. Also, to review the status of the approval process in Europe...
Adjuvant intraperitoneal chemotherapy for advanced primary gastric cancerP H Sugarbaker
Washington Cancer Institute, 106 Irving St, NW, Suite 3900, Washington, DC 20010, USA
Scand J Surg 95:270-3. 2006..Also, cancer dissemination caused from the trauma of cancer resection can release viable cancer cells into the free peritoneal cavity; these cells implant and then progress as peritoneal carcinomatosis...
Peritonectomy proceduresP H Sugarbaker
Washington Cancer Institute, Washington, DC 20010, USA
Cancer Treat Res 134:247-64. 2007
Revised guidelines for second-look surgery in patients with colon and rectal cancerPaul H Sugarbaker
Washington Cancer Institute, Washington, DC 20010, USA
Clin Transl Oncol 12:621-8. 2010..A new management plan utilized in patients at high risk for local-regional recurrence may result in a high likelihood of conversion of a second-look cancer-positive patient to a long-term survivor...
Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal originPaul H Sugarbaker
Washington Cancer Institute, Washington, DC 20010, USA
J Surg Oncol 102:576-81. 2010..Also, these patients are recommended for systemic chemotherapy using an oxaliplatin and 5-fluorouracil (FOLFOX) regimen. A major question concerns the proper timing (neoadjuvant vs. adjuvant) of the systemic chemotherapy...
Surgical responsibilities in the management of peritoneal carcinomatosisPaul H Sugarbaker
The Washington Cancer Institute, Washington Hospital Center, Washington, District of Columbia 20010, USA
J Surg Oncol 101:713-24. 2010..Carcinomatosis can be prevented and can be successfully treated using cytoreductive surgery and perioperative chemotherapy...
Pont hepatique (hepatic bridge), an important anatomic structure in cytoreductive surgeryPaul H Sugarbaker
Washington Cancer Institute, Washington Hospital Center, Washington, District of Columbia 20010, USA
J Surg Oncol 101:251-2. 2010..Cancer dissemination on peritoneal surfaces can be treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy. To maximize benefits a complete cancer removal precedes the chemotherapy treatments...
Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approachPaul H Sugarbaker
Washington Cancer Institute, 106 Irving Street, NW, Suite 3900N, Washington, DC 20010, USA
Expert Opin Pharmacother 10:1965-77. 2009..Multiple reports to date document marked survival benefits; a previously lethal condition can be cured in selected patients. Further pharmacologic research and more knowledgeable patient selection for treatment are required...
Epithelial appendiceal neoplasmsPaul H Sugarbaker
Program in Peritoneal Surface Malignancy, Washington Cancer Institute, 106 Irving Street, NW, Suite 3900, WA, DC 20010, USA
Cancer J 15:225-35. 2009..The presence versus absence of lymph nodal metastases on survival have minimal significance (P = 0.0495). These results of treatment can be achieved with a 19% incidence of severe complications and a 2% mortality...
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancerPaul H Sugarbaker
Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington, District of Columbia 20010, USA
Curr Opin Obstet Gynecol 21:15-24. 2009..The conventional treatment approach for advanced ovarian malignancy is surgical debulking and systemic chemotherapy. More than 50% of these patients relapse within 5 years...
Management of mucinous urachal neoplasm presenting as pseudomyxoma peritoneiPaul H Sugarbaker
Washington Cancer Institute, Washington, DC 20010, USA
Tumori 94:732-6. 2008..Mucinous neoplasms of the urachus are rare malignancies so that the physicians' index of suspicion for a timely and accurate diagnosis is low. Also, this disease may present with a wide variety of symptoms and signs...
The porta hepatis as a site of recurrence of mucinous appendiceal neoplasms treated by cytoreductive surgery and perioperative intraperitoneal chemotherapyPaul H Sugarbaker
Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington DC, USA
Tumori 94:694-700. 2008..The goal of this study was to investigate the porta hepatis as a site of recurrence of appendiceal mucinous neoplasms...
Circumferential cutaneous traction for exposure of the layers of the abdominal wallPaul H Sugarbaker
Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
J Surg Oncol 98:472-5. 2008..Clear exposure of the operative field at all stages of a surgical procedure is a requirement of an optimal intervention. Current techniques for retraction do not provide visualization of the abdominal wall...
Thin-walled cysts as a pathognomonic CT finding in cystic mesotheliomaPaul Sugarbaker
Washington Cancer Institute, Washington, DC 20010, USA
Tumori 94:14-8. 2008..Cystic mesothelioma is a rare disease that results in abdominal distention and poorly defined abdominal pain. Diagnosis has always been made by tissue biopsy rather than by radiologic studies...
Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapyP H Sugarbaker
Washington Cancer Institute, Washington, DC 20010, USA
Int J Hyperthermia 23:431-42. 2007..Much work needs to be done to identify a proper clinical perspective on hyperthermia used with chemotherapy in patients with peritoneal surface malignancy...
Strategies for the prevention and treatment of peritoneal carcinomatosis from gastrointestinal cancerPaul H Sugarbaker
Washington Cancer Institute, Washington, District of Columbia 20010, USA
Cancer Invest 23:155-72. 2005..In the past, this clinical situation was treated only with palliative intent...
Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapyPaul H Sugarbaker
Program in Peritoneal Surface Malignancy, Washington Cancer Institute, 110 Irving St, NW Washington, DC 20010, USA
Oncologist 10:112-22. 2005..Innovative treatment strategies can improve the outcome of patients with peritoneal surface malignancy...
Avoiding carcinogen exposure with intraperitoneal paclitaxelOswald A Stuart
Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA
Oncol Nurs Forum 32:44-8. 2005..Previous studies have documented the leaching of DEHP from PVC-based containers and extension sets during the IV administration of paclitaxel...
The subpyloric space: an important surgical and radiologic feature in pseudomyxoma peritoneiP H Sugarbaker
The Washington Cancer Institute, Washington, D C 20010, USA
Eur J Surg Oncol 28:443-6. 2002..In some patients mucinous tumour that surrounds the stomach is an important consideration in accomplishing a complete cytoreduction...
Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancerPaul H Sugarbaker
Washington Cancer Institute, Washington, DC, USA
Semin Surg Oncol 21:233-48. 2003..Sufficient data are available from the gastric cancer literature to support the use of these combined treatments on a routine basis if the primary cancer is resectable and gastrointestinal function can be reestablished...
Peritonectomy proceduresPaul H Sugarbaker
Program in Peritoneal Surface Malignancy, Washington Cancer Institute, 100 Irving St, NW, Suite CG 185, Washington, DC 20010, USA
Surg Oncol Clin N Am 12:703-27, xiii. 2003..Several different procedures are required in a single surgical event that may require 8-12 hours. Their use depends on the distribution and extent of invasion of the malignancy disseminated within the peritoneal space...
Carcinomatosis from gastrointestinal cancerPaul H Sugarbaker
Washington Cancer Institute, Washington, DC 20010, USA
Ann Med 36:9-22. 2004..One may conclude that selected patients with carcinomatosis should expect longterm survival with a combined treatment approach using cytoreductive surgery with perioperative intraperitoneal chemotherapy...
Cytoreduction including total gastrectomy for pseudomyxoma peritoneiP H Sugarbaker
Washington Cancer Institute, 110 Irving Street NW, Washington, DC 20010, USA
Br J Surg 89:208-12. 2002..In some patients, the stomach and/or its vascular supply are so covered by mucinous tumour that total gastrectomy is required for complete resection...
Transureteroureterostomy: an adjunct to the management of advanced primary and recurrent pelvic malignancyPaul H Sugarbaker
Washington Cancer Institute, 110 Irving St NW, Washington, DC 20010, USA
Int J Colorectal Dis 18:40-4. 2003..With unilateral involvement, reconstruction of the ureters with salvage of the ipsilateral renal function should be considered...
A review of peritoneal mesothelioma at the Washington Cancer InstitutePaul H Sugarbaker
Program in Peritoneal Surface Malignancy, Washington Cancer Institute, 110 Irving St, NW, Washington, DC 20010, USA
Surg Oncol Clin N Am 12:605-21, xi. 2003..Female patients had a significantly better prognosis than males. The other significant predictive factors of survival were: age, diagnosis by incidental findings, tumor extent, pathology, and completeness of cytoreduction...
Central venous access through the right gonadal veinPaul H Sugarbaker
Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
J Surg Oncol 79:71. 2002
Pedunculated peritoneal surface polyps in pseudomyxoma peritonei syndromeP H Sugarbaker
The Washington Cancer Institute, Washington, DC 20010, USA
Histopathology 39:525-8. 2001..The purpose of this study was to examine the mechanism whereby the small bowel remains free of gross tumour and peritoneal surface polyps form...
Managing the peritoneal surface component of gastrointestinal cancer. Part 2. Perioperative intraperitoneal chemotherapyPaul H Sugarbaker
Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington, DC, USA
Oncology (Williston Park) 18:207-19; discussion 220-2, 227-8, 230. 2004..The results of combined treatment as they vary in mucinous and nonmucinous tumors are also discussed...
Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancerRodrigo Gomes da Silva
Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
J Am Coll Surg 203:878-86. 2006....
Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancerLana Bijelic
Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA
Ann Surg Oncol 14:2281-8. 2007..The aim of this study was to analyze the anatomic distribution, timing, and outcomes of recurrent disease after complete cytoreduction and perioperative intraperitoneal chemotherapy (PIC) for peritoneal carcinomatosis of colorectal origin...
Third look surgery and beyond for appendiceal malignancy with peritoneal disseminationFaheez Mohamed
The Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
J Surg Oncol 83:5-12; discussion 12-3. 2003..However, after four or more interventions, the effects of tumor biology may predominate. Although 5-year survival is likely with multiple reoperations, prolonged follow-up shows that cancer cure is a rare event...
Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasmsTristan D Yan
Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington Hospital Center, 106 Irving Street NW, Suite 3900N, Washington, DC 20010, USA
Ann Surg Oncol 14:2289-99. 2007..The objective of this data analysis was to study treatment failure after complete cytoreduction for peritoneal dissemination from appendiceal mucinous neoplasms...
Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokineticsVinicius de Lima Vazquez
Washington Cancer Institute, Washington DC, USA
Cancer Chemother Pharmacol 52:108-12. 2003..The pharmacological barrier between the abdominopelvic cavity and plasma is not directly related to an intact peritoneum...
Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinomaTristan D Yan
Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington, DC, USA
J Clin Oncol 24:4011-9. 2006....
Perioperative outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy for non-appendiceal peritoneal carcinomatosis from a prospective databaseTristan D Yan
Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington Hospital Center, Washington, District of Columbia 20010, USA
J Surg Oncol 96:102-12. 2007..An accurate assessment of perioperative outcomes is crucial for integration of this combined procedure into clinical practice...
Tailgut cyst, an unusual cause of pseudomyxoma peritoneiLuis Zappa
Washington Cancer Institute, Washington, DC 20010, USA
Tumori 95:514-7. 2009..Retrorectal hamartoma, also known as tailgut cyst, is a rare tumor that arises from remnants of the embryonic postanal gut. The tumor occurs in the retrorectal space and may undergo malignant degeneration...
Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasmsLana Bijelic
Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington Hospital Center, Washington, District of Columbia
J Surg Oncol 98:295-9. 2008..Despite its efficacy, recurrences remain a common problem...
Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma--a prospective study of 70 consecutive casesTristan D Yan
Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, Suite 3900N, Washington, DC 20010, USA
Ann Surg Oncol 14:515-25. 2007....
Rectus abdominis muscle resection for abdominal wall recurrence of mucinous adenocarcinoma or peritoneal mesotheliomaTristan Yan
Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
Tumori 94:309-13. 2008..With follow-up these entrapped cancer cells may progress as an abdominal wall recurrence of the disease process. Frequently, laparoscopy is the definitive diagnostic study which results in the abdominal wall cancer progression...
Discordant histology of primary appendiceal adenocarcinoid neoplasms with peritoneal disseminationTristan D Yan
Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA
Ann Surg Oncol 15:1440-6. 2008..The objective of the present study was to quantitate these discordant histopathological findings and examine its clinical implication...
Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapyTristan D Yan
Program in Peritoneal Surface Malignancy, Department of Surgical Oncology, Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
Cancer 103:839-49. 2005..Because adequate cytoreduction is necessary to achieve prolonged survival, CT scans became an accurate prognostic radiologic test for patient selection for comprehensive treatment...
Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent processFaheez Mohamed
The Washington Cancer Institute, Washington Hospital Center, Washington, District of Columbia 20010, USA
J Surg Oncol 86:10-5. 2004..34, Fisher's exact test) was demonstrated between groups. CONCLUSIONS: Further investigation of pseudomyxoma peritonei at a molecular and genetic level may help to formulate a more comprehensive classification...
Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesotheliomaTristan D Yan
Washington Hospital Center, Washington Cancer Institute, 106 Irving Street, NW, Suite 3900N, Washington, DC 20010, USA
Ann Surg Oncol 14:41-9. 2007....
Limited survival in the treatment of carcinomatosis from rectal cancerRodrigo Gomes da Silva
Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
Dis Colon Rectum 48:2258-63. 2005..Some improvement in these poor results may occur if resection of a rectal cancer with carcinomatosis is delayed until definitive treatment of the primary cancer plus the carcinomatosis is possible...
Cytoreduction of the small bowel surfacesLana Bijelic
Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington, DC, USA
J Surg Oncol 97:176-9. 2008
Clinical presentation of peritoneal mesotheliomaYair I Z Acherman
The Washington Cancer Institute, Washington Hospital Center, DC 20010, USA
Tumori 89:269-73. 2003..CONCLUSIONS: Pain was the most common initial presenting symptom, with increased abdominal girth as a second. A more favorable prognosis occurred in women with a small disease volume...
Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experiencePaul H Sugarbaker
Washington Cancer Institute, Washington, DC 20010, USA
Semin Oncol 29:51-61. 2002..A prolonged high quality of life is possible in the majority of patients...
Comprehensive approach to advanced primary and recurrent ovarian cancer: a personal experienceC Pablo Carmignani
Washington Cancer Institute, 110 Irving Street NW, Washington, DC 20010, USA
Expert Rev Anticancer Ther 4:477-87. 2004..Patients that received a complete cytoreduction followed by perioperative intraperitoneal chemotherapy had an improved survival, with reasonable morbidity and mortality, as compared with those who received incomplete cytoreduction...
Optimizing the factors which modify thermal enhancement of melphalan in a spontaneous murine tumorFaheez Mohamed
The Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, 3900N, Washington, DC 20010, USA
Cancer Chemother Pharmacol 58:719-24. 2006..5 degrees C may optimize anti-neoplastic activity. These data may be useful in formulating clinical protocols in which melphalan and heat are combined...
Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancyKurt Van Der Speeten
Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
Curr Drug Discov Technol 6:72-81. 2009..Timing of the chemotherapy as a planned part of the surgical procedure to maximize exposure of all peritoneal surfaces is crucial to success...
Intraperitoneal taxanesFaheez Mohamed
Washington Cancer Institute, Washington Hospital Center, 110 Irving Street, NW, Washington, DC 20010, USA
Surg Oncol Clin N Am 12:825-33. 2003..Docetaxel requires further Phase II study, but its impressive activity with systemic administration may be optimized with intraperitoneal administration for the treatment of peritoneal surface malignancy...
Computed tomographic characterization of malignant peritoneal mesotheliomaTristan Dongbo Yan
Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington Hospital Center, DC 20010, USA
Tumori 91:394-400. 2005..With the use of the Z-score and interpretative small bowel findings a radiologic characterization of this disease for primary radiologic diagnosis is possible...
Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin CO Anthony Stuart
Washington Cancer Institute, Occupational and Environmental Medicine, Washington Hospital Center, Washington, DC 20010, USA
Ann Surg Oncol 9:186-91. 2002..The least permeable gloves leaked a mean of 3.8 parts per million over 90 minutes. CONCLUSIONS: No detectable safety hazard to the surgeon or other operating room personnel was demonstrated...
Total anterior parietal peritonectomyVinicius de Lima Vazquez
Washington Cancer Institute, Washington, District of Columbia 20010, USA
J Surg Oncol 83:261-3. 2003
Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendixC Pablo Carmignani
Washington Cancer Institute, Washington, DC 20010, USA
J Surg Oncol 87:162-6. 2004..These tumor markers have practical value in the management of epithelial appendiceal malignancy with peritoneal dissemination...
Cholecystectomy, lesser omentectomy, and stripping of the omental bursa: a peritonectomy procedureVinicius de Lima Vazquez
Washington Cancer Institute, Washington, DC 20010, USA
J Surg Oncol 84:45-9. 2003
Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutionsFaheez Mohamed
The Washington Cancer Institute, Washington Hospital Center, 110 Irving Street, NW, Washington, DC 20010, USA
Cancer Chemother Pharmacol 52:405-10. 2003..Clinical investigations into the use of 6% hetastarch with high molecular weight chemotherapeutic agents are warranted...
Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesotheliomaCarlos A Cerruto
Department of Pathology, Washington Hospital Center, Washington, DC 20010, USA
Arch Pathol Lab Med 130:1654-61. 2006..Nuclear/nucleolar size was found to be a reliable histomorphologic assessment available to assess prognosis in these patients...
Adjuvant intraperitoneal chemotherapy: a reviewPaul H Sugarbaker
Washington Cancer Institute, Washington, DC 20010, USA
Recent Results Cancer Res 169:83-9. 2007
Clinical perspective on desmoplastic small round-cell tumorAlberto Gil
Washington Cancer Institute, Washington, DC 20010, USA
Oncology 67:231-42. 2004....
Pharmacokinetic and phase II study of heated intraoperative intraperitoneal melphalanPaul H Sugarbaker
Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
Cancer Chemother Pharmacol 59:151-5. 2007..The use of heated intraoperative intraperitoneal melphalan may provide a pharmacokinetic and clinical advantage in this group of gastrointestinal cancer patients who cannot be made cancer-free with cytoreductive surgery...
Re: Verwaal VJ, van Tinteren H, Ruth SV, et al.: Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004; 85:61-67Paul H Sugarbaker
J Surg Oncol 88:276-8. 2004
Are there curative options to peritoneal carcinomatosis?Paul H Sugarbaker
Ann Surg 242:748-50; author reply 750-1. 2005
Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancyOlivier Glehen
Surgical Department, Centre Hospitalo-Universitaire Lyon Sud, , France
Ann Surg 240:278-85. 2004..Patients with signet ring histology or lymph node involvement have an especially poor outcome. Repeat cytoreduction and intraperitoneal chemohyperthermia may improve outcome...
[Treatment results of peritoneal dissemination from gastric cancer by neoadjuvant intraperitoneal-systemic chemotherapy]Yutaka Yonemura
Peritoneal Dissemination Program, Shizuoka Cancer Center
Gan To Kagaku Ryoho 31:1723-6. 2004..This procedure is most appropriate for highly motivated patients who are committed to survive as long as possible...
van Ruth S, Bronkhorst MWGA, van Coeverden F, Zoetmulder FAN. Peritoneal benign cystic mesothelioma: a case report and review of literature. Eur J Surg Oncol 2002; 28(2): 192-5Kauimarz Sethna
Eur J Surg Oncol 28:897. 2002
Carcinomatosis--is cure an option?Paul H Sugarbaker
J Clin Oncol 21:762-4. 2003
Peritoneum as the first-line of defense in carcinomatosisPaul H Sugarbaker
J Surg Oncol 95:93-6. 2007
An evolving role of perioperative intraperitoneal chemotherapy after cytoreductive surgery for colorectal peritoneal carcinomatosisTristan D Yan
Ann Surg Oncol 14:2171-2. 2007
A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancerTristan D Yan
Department of Surgery, University of New South Wales, St George Hospital, Sydney, NSW, Australia
Ann Surg Oncol 14:2702-13. 2007..The purpose of this systematic review and meta-analysis was to determine the effectiveness and safety of adjuvant intraperitoneal chemotherapy for patients with locally advanced resectable gastric cancer...
Management of peritoneal surface malignancy. PrefacePaul H Sugarbaker
Surg Oncol Clin N Am 12:xxi-xxiv. 2003
Local-regional approach to diffuse malignant peritoneal mesotheliomaPaul H Sugarbaker
Gastroenterol Clin Biol 31:780-1. 2007
